First Majestic Q2 Surge Prompts Upgrade, but Silver Price Dependency Persists

What happened

First Majestic Silver reported robust Q2 2026 results with EBITDA up 110% and $194.6 million in free cash flow, supported by higher realized metal prices, while asset sales boosted its cash position to $1.09 billion, and the company raised its full-year guidance, prompting an upgrade to Buy by a Seeking Alpha analyst. This performance eases earlier concerns about capital discipline and liquidity, as the strengthened balance sheet and improved guidance suggest near-term financial stress is lower than feared when the DeepValue report last assessed the stock at $22.20. However, the upgrade relies on silver maintaining its elevated price and a broader re-rating of the metal, with the stock still trading at a high P/E of over 60, leaving minimal margin of safety if silver prices correct. The dividend policy remains fully discretionary despite the 2%-of-revenue framework, and the board could still reduce payouts if costs escalate or project spending demands more cash. Consequently, while Q2 numbers are undeniably strong and provide tactical momentum, the stock’s fate remains tightly linked to silver price swings and execution on H2 2026 expansion targets.

Implication

Investors can find tactical upside in AG shares following a robust Q2 that delivered sharp improvements in free cash flow and balance sheet strength, but the Buy thesis rests heavily on sustained elevated silver prices and successful integration of asset sales into future growth. The company’s improved 2026 guidance and $1.09 billion cash position reduce the risk of an immediate capital overreach, yet the dividend policy remains board-discretionary, and the stock’s valuation (P/E around 62) leaves little room for error. A silver price retreat or operational misstep could quickly erode the recent gains. Long-term investors should require evidence that H2 2026 throughput expansions stay on schedule and that the company converts its strengthened balance sheet into per-share value without dilution. Until then, AG is best treated as a tactical silver proxy rather than a durable compounding investment.

Thesis delta

The prior WAIT stance was predicated on near-term dividend credibility and capex discipline risks. Q2 2026 results have partially resolved these concerns, as free cash flow surged and cash reserves expanded to $1.09 billion via asset sales, supporting the company's reinvestment and M&A capacity. However, the upgrade to Buy is contingent on silver's re-rating materializing; absent a higher metal price, valuation remains stretched, and the discretionary dividend introduces ongoing uncertainty.